Schwab Charles Investment Management Inc. raised its stake in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 34.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,514 shares of the company’s stock after purchasing an additional 1,664 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Taro Pharmaceutical Industries were worth $735,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Advisory Services Network LLC increased its position in Taro Pharmaceutical Industries by 2.0% during the second quarter. Advisory Services Network LLC now owns 5,474 shares of the company’s stock worth $613,000 after purchasing an additional 105 shares during the last quarter. Wells Fargo & Company MN increased its position in Taro Pharmaceutical Industries by 11.2% during the second quarter. Wells Fargo & Company MN now owns 1,685 shares of the company’s stock worth $189,000 after purchasing an additional 170 shares during the last quarter. Legal & General Group Plc increased its position in Taro Pharmaceutical Industries by 4.7% during the second quarter. Legal & General Group Plc now owns 8,318 shares of the company’s stock worth $932,000 after purchasing an additional 370 shares during the last quarter. Bank of New York Mellon Corp increased its position in Taro Pharmaceutical Industries by 1.5% during the third quarter. Bank of New York Mellon Corp now owns 30,502 shares of the company’s stock worth $3,438,000 after purchasing an additional 436 shares during the last quarter. Finally, California Public Employees Retirement System increased its position in Taro Pharmaceutical Industries by 1.9% during the second quarter. California Public Employees Retirement System now owns 32,800 shares of the company’s stock worth $3,676,000 after purchasing an additional 600 shares during the last quarter. 13.41% of the stock is owned by hedge funds and other institutional investors.

Taro Pharmaceutical Industries Ltd. (NYSE TARO) opened at $104.58 on Thursday. Taro Pharmaceutical Industries Ltd. has a 52-week low of $94.00 and a 52-week high of $128.46. The company has a market cap of $4,200.00, a P/E ratio of 12.90 and a beta of 0.62.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $1.30 EPS for the quarter. Taro Pharmaceutical Industries had a net margin of 44.07% and a return on equity of 15.66%.

Separately, BidaskClub lowered shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/taro-pharmaceutical-industries-ltd-taro-shares-bought-by-schwab-charles-investment-management-inc/1823297.html.

Taro Pharmaceutical Industries Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.